Imugene: Cancer drug trial green lit by US FDA 

Listen to ASX-listed Imugene Managing Director Leslie Chong talk to Matt Birney on the Bulls N’ Bears Report about Imugene’s “immunotherapy” drug that can laser-target cancerous cells in partnership with an already approved drug, potentially setting up a sublime pairing of products in the vanguard of the fight against cancer.